<DOC>
	<DOC>NCT00002210</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.</brief_summary>
	<brief_title>A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV infection. Plasma HIV1 levels greater than 10,000 copies/ml.</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>